AstraZeneca scraps Rigel arthritis pill in new R&D blow

[riky]

AstraZeneca scraps Rigel arthritis pill in new R&D blow

By Ben Hirschler LONDON (Reuters) - AstraZeneca is ending development of a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing overall results. The decision is a fresh blow to AstraZeneca's already sparse new-drug pipeline and a bigger setback for Rigel Pharmaceuticals, the U.S. biotech firm that struck a licensing deal for fostamatinib with Britain's second-biggest drugmaker in 2010. ...

Source: You are not allowed to view links. Register or Login